免疫抑制状态对口咽癌放疗患者预后的影响:基于人群的回顾性分析
该研究回顾性分析了2011至2016年间在BC Cancer接受放疗的1077例口咽鳞状细胞癌患者,其中5.8%存在免疫抑制。免疫抑制患者的3年总生存率(64.6% vs 79.5%,HR 1.78,p=0.0062)和3年无病生存率均显著更差,疾病复发率更高(44.4% vs 24.9%,HR 2.12,p=0.0001)。多因素分析显示免疫抑制是更差无病生存的独立预测因素(HR 1.97,p<0.001)。
要点
- 免疫抑制患者3年OS为64.6%,非免疫抑制患者为79.5%(HR 1.78,p=0.0062)。
- 免疫抑制患者3年复发率为44.4%,非免疫抑制患者为24.9%(HR 2.12,p=0.0001)。
- 免疫抑制是更差DFS的独立预测因素(HR 1.97,p<0.001)。
核心结论
- 免疫抑制是口咽鳞状细胞癌放疗患者更差无病生存的独立预测因素。
研究设计与样本
- 回顾性队列研究,纳入2011至2016年BC Cancer接受放疗的全部口咽鳞状细胞癌患者1077例,其中5.8%(n=62)存在免疫抑制。
- 采用Kaplan-Meier法和竞争风险分析评估生存结局,并进行多因素分析和倾向性评分匹配。
主要发现
- 中位随访3.3年,非免疫抑制患者3年OS为79.5%(95%CI 76.8-82.0%),免疫抑制患者为64.6%(95%CI 50.9-75.3%),HR 1.78(95%CI 1.18-2.68),p=0.0062。
- 非免疫抑制患者3年疾病复发率为24.9%(95%CI 22.2-27.7%),免疫抑制患者为44.4%(95%CI 31.5-56.6%),HR 2.12(95%CI 1.45-3.11),p=0.0001。
- 多因素分析显示,主动吸烟、晚期TNM分期、舌根亚部位、p16阴性及未知、无同步化疗、较高Charlson合并症指数和较低放疗剂量均与更差DFS相关(均p<0.05)。
- 免疫抑制患者较非免疫抑制患者DFS更差,p<0.001,HR 1.97(95%CI 1.33-2.91)。
临床怎么用
- 对存在免疫抑制的口咽癌放疗患者,应认识到其DFS和OS更差的风险,可能需要加强随访或考虑个体化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The incidence of immunosuppression in patients with oropharynx head & neck squamous cell carcinoma (SCC) is not well studied. This study evaluates disease characteristics and treatment outcomes in oropharynx SCC in patients with and without immunosuppression. METHODS: A retrospective review of all patients treated with radiotherapy for oropharynx SCC at BC Cancer from 2011 to 2016 was performed. Survival outcomes were assessed using Kaplan-Meier methods and competing risk analysis. Multivariate analysis and propensity score matching were performed. RESULTS: There were 1077 patients, of which 5.8% (n = 62) had an immunosuppressive medical condition or were taking long-term immunosuppressive medication at diagnosis. Median follow-up was 3.3 years. Three year OS for patients without immunosuppression was 79.5% (95% Confidence Interval [CI] 76.8-82.0%) and for those with immunosuppression was 64.6% (95% CI 50.9-75.3%) (hazard ratio [HR] 1.78, 95% CI 1.18-2.68, p = 0.0062). The three year disease recurrence for patients without immunosuppression was 24.9% (95% CI 22.2-27.7%) and 44.4% (95% CI 31.5-56.6%) for those with immunosuppression (HR 2.12, 95% CI 1.45-3.11, p = 0.0001). Multivariate analysis of disease free survival (DFS) found that active smoking, advanced TNM stage, base of tongue subsite, p16 negative and unknown, no concurrent chemotherapy, higher Charlson Comorbidity Index, and lower radiation dose were also associated with worse DFS (all p < 0.05). Immunosuppressed patients had worse DFS relative to patients without immunosuppression, p < 0.001, HR 1.97 (95% CI 1.33-2.91). CONCLUSION: Immunosuppression was an independent predictor of worse DFS in this large cohort of patients with oropharynx SCC.
引用
- Hamilton SN, Urban R, Liu A, et al. Population-based outcomes by immunosuppressed status in patients undergoing radiotherapy for oropharyngeal cancer. Radiother Oncol. 2020. PMID: 32798599. doi:10.1016/j.radonc.2020.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。